Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation

Purpose: To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrel...

Descripción completa

Detalles Bibliográficos
Autores: Martínez, Carmen, Gayoso, Jorge, Canals, Carme, Finel, Hervé, Peggs, Karl, Dominietto, Alida, Castagna, Luca, Afanasyev, Boris, Robinson, Stephen P., Blaise, Didier, Corradini, Paolo, Itala-Rëmës, Maija, Bermudez, Arancha, Forcade, Edouard, Russo, Domenico, Potter, Michael N., McQuaker, Grant, Yakoub-Agha, Ibrahim, Scheid, Christof, Bloor, Adrian, Montoto Almirall, Silvia, Dreger, Peter, Sureda, Anna, European Society for Blood and Marrow Transplantation
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/124236
Acceso en línea:https://hdl.handle.net/2445/124236
Access Level:acceso abierto
Palabra clave:Malaltia de Hodgkin
Trasplantament d'òrgans
Hodgkin's disease
Transplantation of organs
id ES_c749e752d2d7ba56c65c8f635ee06dc1
oai_identifier_str oai:diposit.ub.edu:2445/124236
network_acronym_str ES
network_name_str España
repository_id_str
spelling Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow TransplantationMartínez, CarmenGayoso, JorgeCanals, CarmeFinel, HervéPeggs, KarlDominietto, AlidaCastagna, LucaAfanasyev, BorisRobinson, Stephen P.Blaise, DidierCorradini, PaoloItala-Rëmës, MaijaBermudez, AranchaForcade, EdouardRusso, DomenicoPotter, Michael N.McQuaker, GrantYakoub-Agha, IbrahimScheid, ChristofBloor, AdrianMontoto Almirall, SilviaDreger, PeterSureda, AnnaEuropean Society for Blood and Marrow TransplantationMalaltia de HodgkinTrasplantament d'òrgansHodgkin's diseaseTransplantation of organsPurpose: To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods: We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results: Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P =.04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P =.26) and higher in MUD (P =.003), and risk of relapse was lower in both HAPLO (P =.047) and MUD (P,.001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P =.049) and similar to MUD (38%; P =.59). Conclusion: Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.American Society of Clinical Oncology2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/124236Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1200/JCO.2017.72.6869Journal of Clinical Oncology, 2017, vol. 35, num. 30, p. 3425-3435https://doi.org/10.1200/JCO.2017.72.6869(c) American Society of Clinical Oncology, 2017info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1242362026-05-27T06:46:51Z
dc.title.none.fl_str_mv Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
title Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
spellingShingle Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
Martínez, Carmen
Malaltia de Hodgkin
Trasplantament d'òrgans
Hodgkin's disease
Transplantation of organs
title_short Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
title_full Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
title_fullStr Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
title_full_unstemmed Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
title_sort Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
dc.creator.none.fl_str_mv Martínez, Carmen
Gayoso, Jorge
Canals, Carme
Finel, Hervé
Peggs, Karl
Dominietto, Alida
Castagna, Luca
Afanasyev, Boris
Robinson, Stephen P.
Blaise, Didier
Corradini, Paolo
Itala-Rëmës, Maija
Bermudez, Arancha
Forcade, Edouard
Russo, Domenico
Potter, Michael N.
McQuaker, Grant
Yakoub-Agha, Ibrahim
Scheid, Christof
Bloor, Adrian
Montoto Almirall, Silvia
Dreger, Peter
Sureda, Anna
European Society for Blood and Marrow Transplantation
author Martínez, Carmen
author_facet Martínez, Carmen
Gayoso, Jorge
Canals, Carme
Finel, Hervé
Peggs, Karl
Dominietto, Alida
Castagna, Luca
Afanasyev, Boris
Robinson, Stephen P.
Blaise, Didier
Corradini, Paolo
Itala-Rëmës, Maija
Bermudez, Arancha
Forcade, Edouard
Russo, Domenico
Potter, Michael N.
McQuaker, Grant
Yakoub-Agha, Ibrahim
Scheid, Christof
Bloor, Adrian
Montoto Almirall, Silvia
Dreger, Peter
Sureda, Anna
European Society for Blood and Marrow Transplantation
author_role author
author2 Gayoso, Jorge
Canals, Carme
Finel, Hervé
Peggs, Karl
Dominietto, Alida
Castagna, Luca
Afanasyev, Boris
Robinson, Stephen P.
Blaise, Didier
Corradini, Paolo
Itala-Rëmës, Maija
Bermudez, Arancha
Forcade, Edouard
Russo, Domenico
Potter, Michael N.
McQuaker, Grant
Yakoub-Agha, Ibrahim
Scheid, Christof
Bloor, Adrian
Montoto Almirall, Silvia
Dreger, Peter
Sureda, Anna
European Society for Blood and Marrow Transplantation
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malaltia de Hodgkin
Trasplantament d'òrgans
Hodgkin's disease
Transplantation of organs
topic Malaltia de Hodgkin
Trasplantament d'òrgans
Hodgkin's disease
Transplantation of organs
description Purpose: To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods: We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results: Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P =.04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P =.26) and higher in MUD (P =.003), and risk of relapse was lower in both HAPLO (P =.047) and MUD (P,.001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P =.049) and similar to MUD (38%; P =.59). Conclusion: Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/124236
url https://hdl.handle.net/2445/124236
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1200/JCO.2017.72.6869
Journal of Clinical Oncology, 2017, vol. 35, num. 30, p. 3425-3435
https://doi.org/10.1200/JCO.2017.72.6869
dc.rights.none.fl_str_mv (c) American Society of Clinical Oncology, 2017
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) American Society of Clinical Oncology, 2017
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Society of Clinical Oncology
publisher.none.fl_str_mv American Society of Clinical Oncology
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419144439398400
score 15.301603

Similares en LA Referencia